Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2006, Vol. 28 ›› Issue (6): 817-821.

• Original Articles • Previous Articles     Next Articles

Effects of Rosiglitazone on the Expression Connective Tissue Growth actor in Tubulointerstitium in KKAy Mice

QIN Yan, LI Xue-wang, WEN Yu-bing, LI Hang, CHEN Li-meng, DUAN Lin, LI Yan   

  1. Department of Nephrology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China
  • Received:2006-02-23 Revised:1900-01-01 Online:2006-12-30 Published:2006-12-30
  • Contact: LI Xue-wang

Abstract: ABSTRACT:Objective To observe the expression of connective tissue growth factor (CTGF) in the tubulointerstitium in type 2 diabetic KKAy mice and the effect of rosiglitazone on it. Methods KKAy and C57BL/6 mice aged 16 weeks (n=5 in each group) were sacrificed as controls before treatment. Another 20 KKAy mice were treated with rosiglitazone (30 mg·kg-1·d-1, n=10) or placebo (n=10). The mice were sacrificed at 20 and 24-week-age (n=5 at each time point). Protein expression of transforming growth factor-β1 (TGF-β1), CTGF, peroxisome proliferator-activated receptor-γ(PPARγ), and fibronectin were assayed by Western blot, while protein CTGF, PPARγ, and α-smooth muscle actin (α-SMA) were assayed by immunohistochemistry in kidney tissue sections. Results Proteinuria was significantly decreased in mice aged 24 weeks treated by rosiglitazone than same-aged mice treated with placebo [(44.53±1.96) vs (63.66±5.57)μg/24 h, P<0.05). The expressions of TGF-β1, CTGF, and fibronectin in mice aged 20 weeks treated with rosiglitazone decreased by 37%, 21%, and 52% than same-aged control (P<0.01), and those were decreased by 61%, 50%, and 51% in mice aged 24 weeks treated with rosiglitazone compared with same-aged control mice (P<0.01). CTGF in the tubulointerstitium were respectively downregulated by 25% nd 44.9% in treated mice aged 20 weeks and 24 weeks compared with the same-aged control mice(P<0.01). The PPARγ appeared in diabetic mice and increased by 18.1% in mice aged 24 weeks and treated with rosiglitazone than the same-aged control mice (P<0.05). Conclusion Heterogeneous rosiglitazone may upregulate the expression of PPARγ in renal cortex, and remarkably inhibit the expressions of CTGF in the tubulointerstitium and renal cortex in diabetic KKAy mice.

Key words: rosiclitazone, peroxisome proliferator activated receptor-γ, diabetic mice, tubulointerstitium, connective tissue crowtd factor